PORTLAND, Ore., May 29, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Radiopharmaceuticals Market by End User (Hospitals and Clinics, Medical Imaging Centers, and
Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) has been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on the stock in […]
Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock […]
HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biotechnology company’s stock. Several other research analysts also recently commented on ATNM. Cantor Fitzgerald reaffirmed an overweight rating […]
HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals […]
Actinium: Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML Patients finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Analysts' Weekly Ratings Changes for Actinium Pharmaceuticals (ATNM) modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Upgraded by StockNews.com dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to Hold by StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cantor Fitzgerald reissued their overweight rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research report report published on Tuesday morning, Benzinga reports. The firm currently has a $21.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Actinium Pharmaceuticals’ FY2024 earnings at ($1.35) EPS. Several other analysts […]